1588866-45-8
Chemical Structure
GTCpFE
- CAS No.: 1588866-45-8
- Formula:C22H20O8
- Molecular Weight:412.39
InChIKey: ZBZZFYBZJGLZIB-OUKQBFOZSA-N
SMILES: O=C(OC1=CC=C(COC(/C=C/C(OCC)=O)=O)C=C1)C2=C(OC(C)=O)C=CC=C2
Biological Activity: GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44+ CD24- immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GTCpFE | GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44+ CD24- immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kastrati I, et al. Design and synthesis of hybrid drugs to target inflammatory pathways in breast cancer[J]. Cancer Research, 2015, 75(15_Supplement): 4497-4497.
- [2]. Kastrati I, et al. A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. BMC Cancer. 2015 Nov 4;15:845. [Content Brief]
